Peptides explained in plain language
Not medical advice
FDA-approvedCompounded · Rx

Peptides in a TRT plan: what each one does

Testosterone isn't a peptide, but TRT clinics often add peptides to a plan. Here's what each one is meant to do and what to ask.

Key takeaways

  • Testosterone is a steroid hormone, not a peptide, but some TRT plans add peptides alongside it.
  • hCG is an FDA-approved prescription product, while gonadorelin and sermorelin are compounded on prescription.
  • Some peptides offered by clinics, like ipamorelin and CJC-1295, aren't eligible for compounding.
  • Ask your clinic what each product is for, whether it's approved, and how it will be monitored.

Testosterone replacement therapy, or TRT, treats low testosterone. Testosterone itself is a steroid hormone, not a peptide. But many clinics now offer peptides as part of a TRT plan. If your plan lists several products, it helps to know what each one is meant to do.

This article explains the roles in general terms. Your prescriber decides what fits you, and how.

Why add anything to testosterone?

When you take testosterone from outside the body, your brain often cuts back the signal that tells the testicles to make their own. Over time that can shrink the testicles and lower sperm production. Some add-ons aim to keep that natural system working, especially for men who want to protect fertility.

Common add-ons and their roles

What it’s meant to do U.S. status
hCG Acts like the body’s signal to the testicles, prompting them to keep working FDA-approved, prescription only
Gonadorelin Copies a brain hormone that tells the pituitary to signal the testicles No approved product sold now; compounded on prescription
Sermorelin Prompts the body to release growth hormone Once approved, withdrawn for business reasons; compounded on prescription
Ipamorelin, CJC-1295 Marketed to raise growth hormone Not eligible for compounding

A few notes on these:

  • hCG is approved for certain conditions, including a form of low testosterone caused by the pituitary gland. Using it alongside TRT is an off-label choice your prescriber makes.
  • Gonadorelin is offered by some clinics as an alternative to hCG. Because it is compounded, FDA hasn’t reviewed the specific product for safety or effectiveness.
  • Growth hormone–releasing peptides are a separate goal from testosterone. They may raise blood sugar and cause fluid retention, and could in theory encourage existing tumors to grow.
Approved, compounded and research are different things. An approved drug has been reviewed by FDA. A compounded drug is made by a pharmacy for a patient and isn’t FDA-approved. A “research peptide” isn’t meant for people at all.
Get the weekly peptide brief

What changed in the rules, what new research says, and which claims to ignore. One email a week.

Questions to ask your clinic

  • What is each product in my plan for, and what happens if I skip it?
  • Which items are FDA-approved and which are compounded?
  • Which pharmacy makes my compounded products, and is it state-licensed or an FDA-registered outsourcing facility?
  • Is fertility a concern for me now or later, and how does this plan affect it?
  • What blood tests will you check, and how often?
  • What side effects should make me call you?
  • Is any part of this plan something I could safely leave out?

A good clinic will welcome these questions. If the answers are vague, or the plan seems built around selling add-ons, a second opinion from a urologist or endocrinologist is reasonable.

The bottom line

Peptides in a TRT plan play different roles, and they don’t all have the same level of FDA review. Know what each one is for, whether it’s approved or compounded, and how you will be monitored. Your prescriber and pharmacist are the right people to walk you through the details.

This article is for general education and isn’t medical or legal advice. It was written with AI assistance and may contain errors, so check anything that matters against the sources above and with a qualified healthcare professional before starting, stopping or changing any treatment. Why we say this.

Chris Janowski
About the author

Chris Janowski, owner and editor in chief

Chris Janowski is the editor in chief of Peptide Consumer Center. He started the site to give people a plain-language, well-sourced place to learn what peptides are, how they’re regulated and what the evidence actually says. Articles are written with AI assistance and published under his name.

Peptide Consumer Center is owned by Chris Janowski, who also owns PureVitaX, an online store that sells peptides, including several covered on this site. We link to PureVitaX, and Chris benefits when you buy there. Disclosures.